Boehringer Ingelheim Pharma GmbH & Co. KG, CNS Diseases Research Germany, Birkendorferstr. 65, 88397, Biberach an der Riß, Germany.
SynapCell SAS, Biopolis and Institut Jean Roget, Université Joseph Fourier-Grenoble 1, Domaine de la merci, 38700, La Tronche, France.
Neuropharmacology. 2020 Jul;171:108072. doi: 10.1016/j.neuropharm.2020.108072. Epub 2020 Mar 31.
Quantitative Electroencephalography (qEEG) and event-related potential (ERP) assessment have emerged as powerful tools to unravel translational biomarkers in preclinical and clinical psychiatric drug discovery trials. The aim of the present study was to compare the GluN2B negative allosteric modulator (NAM) traxoprodil (CP-101,606) with the unselective NMDA receptor channel blocker S-ketamine to give insight into central target engagement and differentiation on multiple EEG readouts. For qEEG recordings telemetric transmitters were implanted in male Wistar rats. Recorded EEG data were analyzed using fast Fourier transformation to determine power spectra and vigilance states. Additionally, body temperature and locomotor activity were assessed via telemetry. For recordings of auditory event-related potentials (AERP) male C57Bl/6J mice were chronically implanted with deep electrodes using a tethered system. Power spectral analysis revealed a significant increase in gamma power following ketamine treatment, whereas traxoprodil (6&18 mg/kg) induced an overall decrease primarily within alpha and beta bands. Additionally, ketamine disrupted sleep and enhanced time spent in wake vigilance states, whereas traxoprodil did not alter sleep-wake architecture. AERP and mismatch negativity (MMN) revealed that ketamine (10 mg/kg) selectively disrupts auditory deviance detection, whereas traxoprodil (6 mg/kg) did not alter MMN at clinically relevant doses. In contrast to ketamine treatment, traxoprodil did not produce hyperactivity and hypothermia. In conclusion, ketamine and traxoprodil showed very different effects on diverse EEG readouts differentiating selective GluN2B antagonism from non-selective pan-NMDA-R antagonists like ketamine. These readouts are thus perfectly suited to support drug discovery efforts on NMDA-R and understanding the different functions of NMDA-R subtypes.
定量脑电图 (qEEG) 和事件相关电位 (ERP) 评估已成为揭示临床前和临床精神药物发现试验中转译生物标志物的有力工具。本研究旨在比较 GluN2B 负变构调节剂 (NAM) traxoprodil (CP-101,606) 与非选择性 NMDA 受体通道阻滞剂 S-氯胺酮,以深入了解多种 EEG 读数的中枢靶标结合和差异。对于 qEEG 记录,使用遥测发射器植入雄性 Wistar 大鼠。使用快速傅里叶变换分析记录的 EEG 数据以确定功率谱和警觉状态。此外,通过遥测评估体温和运动活动。对于听觉事件相关电位 (AERP) 的记录,使用带有系绳系统的深部电极对雄性 C57Bl/6J 小鼠进行慢性植入。功率谱分析显示氯胺酮治疗后伽马功率显着增加,而 traxoprodil (6&18mg/kg) 主要在 alpha 和 beta 频段引起整体下降。此外,氯胺酮扰乱睡眠并增加清醒警觉状态的时间,而 traxoprodil 不会改变睡眠-觉醒结构。AERP 和失匹配负波 (MMN) 表明,氯胺酮 (10mg/kg) 选择性破坏听觉偏差检测,而 traxoprodil (6mg/kg) 在临床相关剂量下不会改变 MMN。与氯胺酮治疗相比,traxoprodil 不会产生多动和体温过低。总之,氯胺酮和 traxoprodil 对不同的 EEG 读数表现出非常不同的影响,从而区分选择性 GluN2B 拮抗作用与非选择性 pan-NMDA-R 拮抗剂,如氯胺酮。这些读数非常适合支持 NMDA-R 的药物发现工作并理解 NMDA-R 亚型的不同功能。